Beigene Ltd
NASDAQ:BGNE

Watchlist Manager
Beigene Ltd Logo
Beigene Ltd
NASDAQ:BGNE
Watchlist
Price: 184.71 USD 0.49% Market Closed
Market Cap: $21.3B

Operating Margin

2.6%
Current
Improving
by 44.4%
vs 3-y average of -41.8%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
2.6%
=
Operating Income
¥1B
/
Revenue
¥35.7B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
2.6%
=
Operating Income
$1B
/
Revenue
¥35.7B

Peer Comparison

Country Company Market Cap Operating
Margin
CN
Beigene Ltd
HKEX:6160
288.5B HKD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
389.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.3B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
170.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
88.6B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.5B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.4B USD
Loading...

Market Distribution

In line with most companies in China
Percentile
43rd
Based on 8 544 companies
43rd percentile
2.6%
Low
-409 046.1% — -1.4%
Typical Range
-1.4% — 10.3%
High
10.3% — 876.4%
Distribution Statistics
China
Min -409 046.1%
30th Percentile -1.4%
Median 4.2%
70th Percentile 10.3%
Max 876.4%

Beigene Ltd
Glance View

Market Cap
21.3B USD
Industry
Biotechnology

BeiGene Ltd., a biopharmaceutical company with origins in Beijing, stands as a prominent player in the global fight against cancer. Founded in 2010, BeiGene has strategically positioned itself as an innovator in the field of oncology, focusing on molecularly targeted and immuno-oncology drug candidates. The company’s journey began with the vision to challenge the conventional barriers to cancer treatment, particularly in emerging markets where access to advanced therapeutics was limited. Its pipeline, robust with both internally developed and in-licensed candidates, reflects an ambitious approach to tackling various forms of cancer, including but not limited to hematological malignancies and solid tumors. The company generates revenue by developing, manufacturing, and commercializing innovative cancer therapies. BeiGene's business model is multifaceted; it involves in-house development and collaborations with international pharmaceutical giants. A significant portion of its revenue is derived from strategic partnerships, such as co-development and commercialization agreements, which allow the company to expand its market reach. Moreover, BeiGene invests heavily in research and development, which not only drives the discovery of new therapies but also strengthens its competitive edge in the pharmaceutical landscape. By balancing scientific advancement with keen market strategies, BeiGene aims to bridge the gap in global cancer care, aspiring to make life-saving treatments accessible to more patients across diverse geographies.

BGNE Intrinsic Value
148.86 USD
Overvaluation 19%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
2.6%
=
Operating Income
¥1B
/
Revenue
¥35.7B
What is Beigene Ltd's current Operating Margin?

The current Operating Margin for Beigene Ltd is 2.6%, which is above its 3-year median of -41.8%.

How has Operating Margin changed over time?

Over the last 3 years, Beigene Ltd’s Operating Margin has increased from -141.4% to 2.6%. During this period, it reached a low of -141.4% on Sep 30, 2022 and a high of 2.6% on Sep 30, 2025.

Back to Top